BioCelerate will work with the FDA through the agency's Public Private Partnership program, which in part is working to streamline the sharing of nonclinical data through the Clinical Data Interchange Standards Consortium (CDISC) Standard for Exchange of Nonclinical Data (SEND), it said.

BioCelerate and the FDA have released two publications on the topic, one of which describes the SEND datasets and another of which describes how to create a database using SEND information.

FDA issues EUA for GSK-Vir COVID-19 mAb treatment
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for the investigational monoclonal antibody (mAb) therapy sotrovimab...

FDA updates requirements for COVID-19 vaccine EUAs
The U.S. Food and Drug Administration (FDA) issued a new guidance document on May 25 that updates previously issued guidance and sets expectations for...

FDA authorizes Pfizer-BioNTech COVID-19 vaccine for adolescents
The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include adolescents...

CDISC, NORD partner to develop data standards for rare diseases
The Clinical Data Interchange Standards Consortium (CDISC) and the National Organization for Rare Disorders (NORD) announced a partnership to develop...

FDA approves 1st cell-based gene therapy for multiple myeloma
On March 27 the U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (Abecma), the first cell-based gene therapy for treating adult...